Skip to main content
SpringerLink
Log in

The CATIE and CUtLASS Studies in Schizophrenia

Results and Implications for Clinicians

  • Leading Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Numerous double-blind studies have compared second-generation antipsychotics (SGAs) with first-generation antipsychotics (FGAs), with most finding better efficacy and tolerability for SGAs. However, these ‘efficacy trials’ were generally short term and included only highly selected patients. Mostly because of weight gain and other metabolic effects of the SGAs, as well as their high acquisition price, the debate on the (cost) effectiveness of the SGAs led to two pragmatic clinical trials with no sponsorship by industry. Both trials had broad inclusion criteria and long follow-up, and tried to mimic clinical routine: CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) and CUtLASS (Cost Utility of the Latest Antipsychotic drugs in Schizophrenia Study).

1493 patients participated in CATIE, an 18-month, double-blind trial comparing the SGAs olanzapine, quetiapine, risperidone and ziprasidone with the FGA perphenazine. If efficacy or tolerability was insufficient, patients were re-randomized to a medication other than the one they previously received. Improvement of psychopathology and of quality of life was only moderate. Overall, 74% of patients discontinued study medication before 18 months, and the median time to discontinuation was 4.6 months. Aside from olanzapine (time to discontinuation 9.2 months), the other SGAs did not differ from each other or from perphenazine. Except for adverse effects as a reason for discontinuation, differences between the SGAs and the FGA were minimal. In CUtLASS, a 12-month open-label trial, 277 patients were randomized to receive an FGA or a SGA. Again, efficacy was rather similar between the two groups, with only limited improvement of psychopathology and quality of life. The authors of both trials concluded that SGAs do not markedly differ from FGAs regarding compliance, quality of life and effectiveness.

The methodological problems of both trials have been discussed extensively. Patients had psychotic symptoms that were moderate in severity and were at least partially treatment resistant. The marginal improvement observed indicated that this population might not be appropriate to detect differences between FGAs and SGAs. Specific issues of CATIE include the exclusion of patients with tardive dyskinesia in the perphenazine arm and the high discontinuation rate. In CUtLASS, the concept of including 13 different FGAs and four SGAs in the respective classes was problematic. It is of interest that the most widely prescribed drug was sulpiride — of the FGAs, this is probably the ‘most atypical’ drug. Aside from the finding that the advantages of the SGAs are not as strong as early trials and marketing suggested or promised, the trials do not provide much helpful information regarding everyday practice. For tardive dyskinesia, no conclusions at all can be drawn. Similarly, methodological problems inhibited the detection of the other major advantage of the SGAs, i.e. the improved subjective well-being/ quality of life while receiving these agents. It is well known that patients’ and doctors’ perspectives differ markedly, and the Quality of Life Scale (QLS), an expert-rated scale used in both trials, might not be sensitive enough to detect the subjective advantages reported by the majority of patients in other trials.

CATIE and CUtLASS suggest that SGAs do not live up to all the previous expectations. However, even if most of these advantages are debatable, the lower risk of tardive dyskinesia and the better subjective effects should be strong enough reasons to favour these drugs. There is no single antipsychotic that is best for every schizophrenia patient, as individual responses differ markedly. For successfully individualized treatment, a multitude of anti-psychotic options are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008; 100: 20–38

    Article  PubMed  Google Scholar 

  2. Naber D. Subjective effects of antipsychotic treatment. Acta Psychiatr Scand 2005; 111: 81–3

    Article  PubMed  Google Scholar 

  3. Karow A, Schindler D, Naber D. What would the patient choose? Subjective comparison of atypical and typical neuroleptics. Pharmacopsychiatry 2006; 39: 47–51

    Article  PubMed  CAS  Google Scholar 

  4. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia (second Compendium). Arlington (VA): APA, 2004: 249–440

    Google Scholar 

  5. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005; 6: 132–91

    Google Scholar 

  6. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004; 30: 193–217

    Article  PubMed  Google Scholar 

  7. National Institute for Clinical Excellence (NICE). Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. Clinical Guideline 1, National Collaborating Centre for Mental Health. London: NICE, 2002

    Google Scholar 

  8. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005; 39: 1–30

    Article  Google Scholar 

  9. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553–64

    Article  PubMed  CAS  Google Scholar 

  10. Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159: 103–8

    Article  PubMed  Google Scholar 

  11. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581–9

    Article  PubMed  CAS  Google Scholar 

  12. Leucht S, Barnes T, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209–22

    Article  PubMed  Google Scholar 

  13. Woodward ND, Scot EP, Meltzer HY, et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuro-psychopharmacology 2005; 8: 457–72

    CAS  Google Scholar 

  14. Geddes J, Freemantle N, Harrison P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–6

    Article  PubMed  CAS  Google Scholar 

  15. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23

    Article  PubMed  CAS  Google Scholar 

  16. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079–87

    Article  PubMed  CAS  Google Scholar 

  17. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76

    Article  PubMed  CAS  Google Scholar 

  18. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600–10

    Article  PubMed  Google Scholar 

  19. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163: 611–22

    Article  PubMed  Google Scholar 

  20. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007; 164: 415–27

    Article  PubMed  Google Scholar 

  21. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007; 64: 633–47

    Article  PubMed  CAS  Google Scholar 

  22. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10: 398–9

    Article  Google Scholar 

  23. Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007; 164: 428–36

    Article  PubMed  Google Scholar 

  24. Rosenheck AR, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006; 163: 2080–9

    Article  PubMed  Google Scholar 

  25. Lewis SW, Barnes TRE, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32: 715–23

    Article  PubMed  Google Scholar 

  26. Davies LM, Lewis S, Jones PB, et al. Cost-effectiveness of first-v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry 2007; 191: 14–22

    CAS  Google Scholar 

  27. Kind P. The EuroQoL instrument: an index of health related quality of life. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1996

    Google Scholar 

  28. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990; 3: 247–51

    Article  PubMed  CAS  Google Scholar 

  29. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983; 13: 177–83

    Article  PubMed  CAS  Google Scholar 

  30. Edwards JE, Moore RA. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double-blind trials. BMC Fam Pract 2003; 4: 18

    Article  PubMed  Google Scholar 

  31. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 Oct 8; 366(9493): 1267–78

    Article  PubMed  CAS  Google Scholar 

  32. Casey DE. Implications of the CATIE trial on treatment: extrapyramidal symptoms. CNS Spectr 2006; 11Suppl. 7: 25–31

    PubMed  Google Scholar 

  33. Glick ID. Understanding the results of CATIE in the context of the field. CNS Spectr 2006; 11Suppl. 7: 40–7

    PubMed  Google Scholar 

  34. Meltzer HY, Bobo WV. Interpreting the efficacy findings in the CATIE study: what clinicians should know. CNS Spectr 2006; 11Suppl. 7: 14–24

    PubMed  Google Scholar 

  35. Meyer JM. Strategies for the long-term treatment of schizophrenia: real-world lessons from the CATIE trial. J Clin Psychiatry 2007; 68Suppl. 1: 28–33

    PubMed  Google Scholar 

  36. Möller HJ. Do effectiveness (“real world”) studies on anti-psychotics tell us the real truth? Eur Arch Psychiatry Clin Neurosci 2008; 258: 257–70

    Article  PubMed  Google Scholar 

  37. Nasrallah HA. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. J Clin Psychiatry 2007; 68Suppl. 1: 5–12

    PubMed  CAS  Google Scholar 

  38. Weiden PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry 2007; 68Suppl. 1: 12–9

    PubMed  CAS  Google Scholar 

  39. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991; 48: 739–45

    Article  PubMed  CAS  Google Scholar 

  40. Remington G, Kapur S, Zipursky RB. Pharmacotherapy of first-episode schizophrenia. Br J Psychiatry Suppl 1998; 172: 66–70

    PubMed  CAS  Google Scholar 

  41. Lambert M, Schimmelmann BG, Naber D, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2,960 patients with schizophrenia. J Clin Psychiatry 2006; 67(11): 1690–7

    Article  PubMed  Google Scholar 

  42. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371: 1085–97

    Article  PubMed  CAS  Google Scholar 

  43. National Institute of Mental Health. 12-CGI: Clinical Global Impressions. In: Guy W, Bonato RR, editors. Manual for the ECDEU assessment battery. 2nd rev. ed. Chevy Chase (MD): NIHM, 1970: 12–1–6

    Google Scholar 

  44. Endicott J, Spitzer RL, Fleiss JL, et al. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33(6): 766–71

    Article  PubMed  CAS  Google Scholar 

  45. Voruganti L, Cortese L, Oyewumi L, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000; 43: 135–45

    Article  PubMed  CAS  Google Scholar 

  46. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001; 50: 79–88

    Article  PubMed  CAS  Google Scholar 

  47. Wehmeier PM, Kluge M, Schacht A, et al. Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr Res 2007; 91: 178–86

    Article  PubMed  Google Scholar 

  48. de Haan L, van Nimwegen L, van Amelsvoort T, et al. Improvement of subjective well-being and enduring symptomatic remission: a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry 2008; 41: 125–8

    Article  PubMed  Google Scholar 

  49. Rabinowitz J, Lichtenberg P, Kaplan Z, et al. Rehospita-lization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001; 158: 266–9

    Article  PubMed  CAS  Google Scholar 

  50. Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalisation during maintenance treatment of schizophrenia. Arch Gen Psychiatry 1997; 54: 453–63

    Article  PubMed  CAS  Google Scholar 

  51. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997; 154: 782–91

    PubMed  CAS  Google Scholar 

  52. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414–25

    Article  PubMed  Google Scholar 

  53. Oosthuizen PP, Emsley RA, Maritz JS, et al. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003; 64(9): 1075–80

    Article  PubMed  CAS  Google Scholar 

  54. Rosenheck RA. Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. Br J Psychiatry 2007; 191: 238–45

    Article  PubMed  CAS  Google Scholar 

  55. Lewis S, Lieberman J. CATIE and CUtLASS: can we handle the truth? Br J Psychiatry 2008; 192: 161–3

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors gratefully acknowledge the careful reading and helpful comments of Dr Stefan Leucht. No sources of funding were used to assist in the preparation of this review. Dr Naber has received honoraria from and/or acted as a consultant for AstraZeneca, Eli Lilly, Janssen-Cilag and Pfizer. Dr Lambert has received honoraria from and/or acted as a consultant for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag and Pfizer.

Author information

Authors and Affiliations

  1. Department of Psychiatry and Psychotherapy, Centre for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany

    Dieter Naber & Martin Lambert

Authors
  1. Dieter Naber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Lambert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dieter Naber.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Naber, D., Lambert, M. The CATIE and CUtLASS Studies in Schizophrenia. CNS Drugs 23, 649–659 (2009). https://doi.org/10.2165/00023210-200923080-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200923080-00002

Keywords

Search

Navigation